Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Lymphangioleiomyomatosis × nintedanib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 4 Colorectal Neoplasms 4 Recurrence 3 Carcinoma, Non-Small-Cell Lung 3 Small Cell Lung Carcinoma 2 Radiation Pneumonitis 2 Prostatic Neoplasms 2 Mesothelioma, Malignant 2 Lung Neoplasms 2 Glioblastoma 2 Fallopian Tube Neoplasms 2 Carcinoma, Hepatocellular 2 Breast Neoplasms 2 Uterine Cervical Neoplasms 1 Thyroid Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Sarcoma 1 Ovarian Diseases 1 Oligodendroglioma 1 Neuroendocrine Tumors 1 Neoplasms by Site 1 Neoplasms 1 Neoplasm Metastasis 1 Lymphangioleiomyomatosis 1 Leukemia, Myeloid, Acute 1 Inflammatory Breast Neoplasms 1 Head and Neck Neoplasms 1 Gliosarcoma 1 Esophagogastric Adenocarcinoma 1 Endometrial Neoplasms 1

Interventions

Sirolimus 4 nintedanib 1 Sugars 1 Resveratrol 1 Octreotide 1 Loratadine 1 Letrozole 1 Everolimus 1 Celecoxib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03062943 2022-09-28

LAM

IRCCS Multimedica

Phase 2 Completed

Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡